干扰素移植功能障碍：干扰素与丙型肝炎的终章 - Suppr

Suppr

超能文献

Interferon graft dysfunction: a final chapter for interferon and hepatitis C.

作者信息

Thompson Julie A, Lake John R

机构信息

University of Minnesota, Minneapolis, MN, USA.

出版信息

Hepatol Int. 2014 Apr;8(2):155-7. doi: 10.1007/s12072-014-9535-7. Epub 2014 Apr 6.

DOI:10.1007/s12072-014-9535-7

PMID:26202497

Abstract

摘要

相似文献

Interferon graft dysfunction: a final chapter for interferon and hepatitis C.

Hepatol Int. 2014 Apr;8(2):155-7. doi: 10.1007/s12072-014-9535-7. Epub 2014 Apr 6.

High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Gut. 2007 Feb;56(2):237-42. doi: 10.1136/gut.2006.092064. Epub 2006 Jun 23.

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Hepatol Int. 2014 Apr;8(2):285-92. doi: 10.1007/s12072-013-9496-2. Epub 2013 Dec 27.

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.

Liver Transpl. 2004 Jul;10(7):850-8. doi: 10.1002/lt.20189.

[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon].

Rev Esp Enferm Dig. 1996 Jul;88(7):480-4.

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

Gastroenterology. 2012 May;142(5):1132-1139.e1. doi: 10.1053/j.gastro.2012.01.030. Epub 2012 Jan 25.

Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?

Dig Liver Dis. 2009 May;41(5):345-9. doi: 10.1016/j.dld.2008.09.015. Epub 2009 Jan 21.

Treatment of recurrent hepatitis C.

Liver Transpl. 2002 Oct;8(10 Suppl 1):S28-37. doi: 10.1053/jlts.2002.35860.

Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study.

Transpl Int. 2009 May;22(5):562-7. doi: 10.1111/j.1432-2277.2008.00831.x. Epub 2009 Jan 14.

The effect of pretransplant chronic hepatitis C virus infection treatment on graft and patient survival in renal transplant recipients.

Exp Clin Transplant. 2015 Apr;13 Suppl 1:188-92.

本文引用的文献

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Hepatol Int. 2014 Apr;8(2):285-92. doi: 10.1007/s12072-013-9496-2. Epub 2013 Dec 27.

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

Gastroenterology. 2012 May;142(5):1132-1139.e1. doi: 10.1053/j.gastro.2012.01.030. Epub 2012 Jan 25.

A practical guide to the management of HCV infection following liver transplantation.

Am J Transplant. 2009 Aug;9(8):1707-13. doi: 10.1111/j.1600-6143.2009.02702.x. Epub 2009 Jun 16.

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

Liver Transpl. 2008 Jun;14(6):861-71. doi: 10.1002/lt.21447.

Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.

Hum Pathol. 2007 Mar;38(3):443-52. doi: 10.1016/j.humpath.2006.08.028. Epub 2006 Dec 22.

Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Nature. 2005 Aug 18;436(7053):967-72. doi: 10.1038/nature04082.

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.

Dig Dis Sci. 2005 Apr;50(4):719-26. doi: 10.1007/s10620-005-2563-3.

Transplant Proc. 2004 Nov;36(9):2692-6. doi: 10.1016/j.transproceed.2004.09.058.

Virus interference. I. The interferon.

Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67. doi: 10.1098/rspb.1957.0048.

Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study.

J Autoimmun. 2000 Mar;14(2):189-93. doi: 10.1006/jaut.1999.0360.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Interferon graft dysfunction: a final chapter for interferon and hepatitis C.

作者信息

Thompson Julie A, Lake John R

机构信息

University of Minnesota, Minneapolis, MN, USA.

出版信息

Hepatol Int. 2014 Apr;8(2):155-7. doi: 10.1007/s12072-014-9535-7. Epub 2014 Apr 6.

DOI:10.1007/s12072-014-9535-7

PMID:26202497

Abstract

摘要

相似文献

Interferon graft dysfunction: a final chapter for interferon and hepatitis C.

Hepatol Int. 2014 Apr;8(2):155-7. doi: 10.1007/s12072-014-9535-7. Epub 2014 Apr 6.

High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Gut. 2007 Feb;56(2):237-42. doi: 10.1136/gut.2006.092064. Epub 2006 Jun 23.

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Hepatol Int. 2014 Apr;8(2):285-92. doi: 10.1007/s12072-013-9496-2. Epub 2013 Dec 27.

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.

Liver Transpl. 2004 Jul;10(7):850-8. doi: 10.1002/lt.20189.

[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon].

Rev Esp Enferm Dig. 1996 Jul;88(7):480-4.

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

Gastroenterology. 2012 May;142(5):1132-1139.e1. doi: 10.1053/j.gastro.2012.01.030. Epub 2012 Jan 25.

Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?

Dig Liver Dis. 2009 May;41(5):345-9. doi: 10.1016/j.dld.2008.09.015. Epub 2009 Jan 21.

Treatment of recurrent hepatitis C.

Liver Transpl. 2002 Oct;8(10 Suppl 1):S28-37. doi: 10.1053/jlts.2002.35860.

Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study.

Transpl Int. 2009 May;22(5):562-7. doi: 10.1111/j.1432-2277.2008.00831.x. Epub 2009 Jan 14.

The effect of pretransplant chronic hepatitis C virus infection treatment on graft and patient survival in renal transplant recipients.

Exp Clin Transplant. 2015 Apr;13 Suppl 1:188-92.

本文引用的文献

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Hepatol Int. 2014 Apr;8(2):285-92. doi: 10.1007/s12072-013-9496-2. Epub 2013 Dec 27.

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

Gastroenterology. 2012 May;142(5):1132-1139.e1. doi: 10.1053/j.gastro.2012.01.030. Epub 2012 Jan 25.

A practical guide to the management of HCV infection following liver transplantation.

Am J Transplant. 2009 Aug;9(8):1707-13. doi: 10.1111/j.1600-6143.2009.02702.x. Epub 2009 Jun 16.

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

Liver Transpl. 2008 Jun;14(6):861-71. doi: 10.1002/lt.21447.

Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.

Hum Pathol. 2007 Mar;38(3):443-52. doi: 10.1016/j.humpath.2006.08.028. Epub 2006 Dec 22.

Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Nature. 2005 Aug 18;436(7053):967-72. doi: 10.1038/nature04082.

Dig Dis Sci. 2005 Apr;50(4):719-26. doi: 10.1007/s10620-005-2563-3.

Transplant Proc. 2004 Nov;36(9):2692-6. doi: 10.1016/j.transproceed.2004.09.058.

Virus interference. I. The interferon.

Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67. doi: 10.1098/rspb.1957.0048.

Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study.

J Autoimmun. 2000 Mar;14(2):189-93. doi: 10.1006/jaut.1999.0360.